European Journal of Nuclear Medicine and Molecular Imaging · 2022 · 25 citations · 30 references
MedicineOncologyRadiologyDiagnostic ImagingRadiation DosimetryRadionuclide TherapyHepatobiliary ImagingLiver ImagingMagnetic Resonance ImagingPatient-specific DosimetryRadiation TherapyTumor ImagingImage-guided DosimetryImaging-based DosimetryMicrosphere DeliveryMicrospheresRadiation Dose EstimationTherapeutic DosimetryTransarterial RadioembolizationTumor Dose Distribution
Abstract Purpose Transarterial radioembolization (TARE) is a treatment for liver tumours based on injection of radioactive microspheres in the hepatic arterial system. It is crucial to achieve a maximum tumour dose for an optimal treatment response, while minimizing healthy liver dose to prevent toxicity. There is, however, no intraprocedural feedback on the dose distribution, as nuclear imaging can only be performed after treatment. As holmium-166 ( 166 Ho) microspheres can be quantified with MRI, we investigate the feasibility and safety of performing 166 Ho TARE within an MRI scanner and explore the potential of intraprocedural MRI-based dosimetry. Methods Six patients were treated with 166 Ho TARE in a hybrid operating room. Per injection position, a microcatheter was placed under angiography guidance, after which patients were transported to an adjacent 3-T MRI system. After MRI confirmation of unchanged catheter location, 166 Ho microspheres were injected in four fractions, consisting of 10%, 30%, 30% and 30% of the planned activity, alternated with holmium-sensitive MRI acquisition to assess the microsphere distribution. After the procedures, MRI-based dose maps were calculated from each intraprocedural image series using a dedicated dosimetry software package for 166 Ho TARE. Results Administration of 166 Ho microspheres within the MRI scanner was feasible in 9/11 (82%) injection positions. Intraprocedural holmium-sensitive MRI allowed for tumour dosimetry in 18/19 (95%) of treated tumours. Two CTCAE grade 3–4 toxicities were observed, and no adverse events were attributed to treatment in the MRI. Towards the last fraction, 4/18 tumours exhibited signs of saturation, while in 14/18 tumours, the microsphere uptake patterns did not deviate from the linear trend. Conclusion This study demonstrated feasibility and preliminary safety of a first in-human application of TARE within a clinical MRI system. Intraprocedural MRI-based dosimetry enabled dynamic insight in the microsphere distribution during TARE. This proof of concept yields unique possibilities to better understand microsphere distribution in vivo and to potentially optimize treatment efficacy through treatment personalization. Registration Clinicaltrials.gov, identifier NCT04269499, registered on February 13, 2020 (retrospectively registered).
30
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations
The blood supply of neoplasms in the liver.
C Breedis, Graeme P. Young · PubMed · 2003 · 1.3K citations
Valérie Vilgrain, Héléna Pereira, Eric Assenat et al. · The Lancet Oncology · 2017 · 826 citations
Étienne Garin, Lambros Tselikas, Boris Guiu et al. · The Lancet. Gastroenterology & hepatology · 2020 · 604 citations
Harpreet Wasan, Navesh Sharma, Volker Heinemann et al. · The Lancet Oncology · 2017 · 398 citations · Full text